ClinicalTrials.gg

Program

ulonivirine

Also written as “Ulonivirine”, “ULO” and “MK-8507”.

Its studies are mostly in Infections · Hepatic Insufficiency, led by Merck.

Furthest: phase 3, since Dec 1, 202510 company-led studies, 3 open or runningNext primary completion: Jun 29, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck103 open or runningphase 3since Dec 1, 2025Jun 24, 2014Jun 29, 2027phase 1 · NCT05093972

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 24, 2014First study: phase 1 study in HIV-1 InfectionFirst studyNCT02174159 · 18 enrolled
  2. Sep 21, 2020Phase 2 study in HIV-1 InfectionNCT04564547 · 161 enrolled · United States, France, Switzerland
  3. Oct 18, 2021Phase 1 study in Hepatic InsufficiencyNCT05093972 · 22 planned
  4. Sep 27, 2024Phase 1 study in HealthyNCT06619678 · 36 enrolled · United States
  5. Mar 17, 2025Phase 2 study in Acquired Immunodeficiency SyndromeNCT06891066 · 150 enrolled · United States, Australia, Puerto Rico and more
  6. Dec 1, 2025Phase 3 study in Acquired Immunodeficiency SyndromePhase 3 reachedNCT07266831 · 570 planned · United States, Argentina, Canada and more
  7. Dec 12, 20252 phase 1 studies in HealthyNCT07305831, NCT07334886
  8. Apr 7, 2026Phase 1 study in HealthyNCT07530289 · 12 enrolled · United States
  9. May 12, 2026Phase 1 study in HealthyNCT07595263 · 14 enrolled · United States

Ahead

  1. Jun 29, 2027Primary completion: phase 1 study in Hepatic InsufficiencyNCT05093972
  2. Aug 10, 2027Primary completion: phase 2 study in Acquired Immunodeficiency SyndromeNCT06891066
  3. Feb 1, 2029Primary completion: phase 3 study in Acquired Immunodeficiency SyndromeNCT07266831

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07595263Healthy · United States1CompletedSep 29, 202614
NCT07530289Healthy · United States1CompletedMay 23, 202612
NCT07334886Healthy · United States1CompletedNov 11, 20258
NCT07305831Healthy · United States1CompletedApr 9, 202662
NCT07266831Acquired Immunodeficiency Syndrome · United States, Argentina, Canada and more3RecruitingFeb 1, 2029570
NCT06891066Acquired Immunodeficiency Syndrome · United States, Australia, Puerto Rico and more2Active, not recruitingAug 10, 2027150
NCT06619678Healthy · United States1CompletedJun 23, 202436
NCT05093972Hepatic Insufficiency1Not yet recruitingJun 29, 202722
NCT04564547HIV-1 Infection · United States, France, Switzerland2CompletedJan 30, 2025161
NCT02174159HIV-1 Infection1CompletedJul 16, 201518

How it is read

Names in the registry

  • “Ulonivirine”, 6 entries
  • “ULO”, 2 entries
  • “MK-8507”, 1 entry
  • “[14C]Ulonivirine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
ulonivirine (Merck): development program | ClinicalTrials.gg